117results about "Powder delivery" patented technology

The invention relates to small sized particles. These particles comprise at least on the surface thereof a wall composed of a mixture of at least one protein and at least one polysaccharide which are cross-linked, preferably by interfacial cross-linking with a polyfunctional acylating agent which forms at least amide and ester bonds, and optionally anhydride bonds with amine, hydroxyl or carboxyl functions of the protein and of the polysaccharide, and which comprise hydroxamic groups on the surface thereof for chelating metal ions. These particles can be used in cosmetics or in pharmacy notably for the chelation or release of metal ions.

Topically applicable, aesthetically pleasing/elegant cosmetic/dermatological sunscreen compositions well suited for both effective and SPF-improved UV-photoprotection of human skin, scalp, lips, mucous membranes and/or hair contain (a) an effective UV-photoprotecting amount of at least one UV-A sunscreen and/or at least one UV-B sunscreen and (b) an effective aesthetically and SPF improving amount of glass microspheres, formulated into (c) a topically applicable, cosmetically/dermatologically acceptable vehicle, diluent or carrier therefor.

The invention relates to anti-integrin antibodies which are covalently linked to nanoparticles, wherein these nanoparticles were prior loaded with chemotherapeutic/cytotoxic agents. The antibody-chemotherapeutic agent-nanoparticle conjugates according to the invention, especially wherein the antibody is MAb DI17E6 and the cytotoxic agent is doxorubicin show a significant increase of tumor cell toxicity.

Pharmaceutical composition comprising micro particles having an average diameter ranging from 40 to 150 nm, consisting of one or more lipids, a drug and, optionally, a steric stabilizer, suitable to the transmucosal passage and to the overcoming of the blood-brain barrier and the blood-cerebrospinal fluid barrier, said micro particles being obtained dispersing in an aqueous medium cooled to 2-4° C. an oil/water or a water/oil/water micro emulsion comprising said constituents.

Bioavailability of Coenzyme-Q10 (“Co-Q10”), an oil-soluble substance, can be enhanced in a subject by modifying, e.g. nanonizing or charging, the form of Co-Q10. Co-Q10 bioavailability also can be enhanced by administering Co-Q10 to the subject as an oil (lipid)-based and water (hydro)-based mixed composition, along with other optional components, such as oils, resins and other carriers. Accordingly, the invention provides various Co-Q10 compositions, e.g. compositions comprised of (i) Co-Q10 dissolved in one or more Co-Q10-soluble oils and (ii) Co-Q10 in admixture with at least one water-dispersible agent. A Co-Q10 complex of the invention, therefore, yields an increased cell absorption rate, as well as an enhanced percentage of Co-Q10 peak absorption, compared to previously known compounds. Methods for making and using the aforementioned compositions also are provided.

Hydrotropic polymer micelles effective for increasing the water solubility of poorly soluble drugs are described. Such hydrotropic polymer micelles have the combined properties of polymer micelles and hydrotropic agents, which display a synergistic effect for increasing the solubility of such drugs. Hydrotropic polymer micelles are formed in solution from amphiphilic copolymers that comprise a hydrophilic polymer and a hydrophobic polymer having pendant hydrotropic agents. A preferred copolymer is a di-, tri- or multi-block copolymer composed of hydrophilic and hydrophobic polymer chains. A particularly preferred hydrophilic chain comprises polyethyleneoxide (PEG) and a preferred hydrophobic chain comprises hydrotropic monomer units derived from nicotinamide. The micelles are found to be much more effective in solubilizing poorly soluble drugs and exhibit an excellent long-term stability even at high loading of drugs. A hydrotropic polymer micelle has nanometer scale size, by which they can deliver poorly soluble drugs to the body through diverse routes of administration.

The present invention includes a controlled-release composition having a matrix. The matrix contains a pharmaceutically effective amount of an active agent or a pharmaceutically acceptable salt, solvate, ester, and/or prodrug thereof, an ionic non-gelling matrix polymer, and a pH modifier. The ionic non-gelling matrix polymer is practically insoluble and unswellable at a first aqueous fluid pH and is soluble at a second aqueous fluid pH. The pH modifier is present in an amount to control the release of the active agent from the composition. The controlled-release composition is substantially free of a gelling or swellable excipient. The present invention also provides methods of making and using the controlled-release compositions.

Methods are provided for preparing spray-dried, drug-containing particles comprising the steps of selecting (i) a drug and an optional excipient, wherein the combination of the drug and optional excipient has an effective pI, and (ii) an aqueous solution having a pH that is different from the effective pI; (b) combining the solution and the drug and optional excipient, wherein an absolute net charge is associated with the drug and optional excipient as a result of an absolute difference between the pH and effective pI; and (c) spray drying the solution to form the spray-dried, drug-containing particles. Particles and compositions comprising the prepared particles as well as methods of use are also provided.

The present invention provides a pharmaceutical composition of a practically insoluble drug, wherein the composition may be administered with food or without food. The composition may be in the form of a solid dispersion of the practically insoluble drug and a polymer having acidic functional groups, and the composition may in vitro form a suspension.

In on aspect, the invention includes a microcarrier bead having a porous three-dimensional core having (a) a polymeric porous three-dimensional body having porosity of about 15 to about 90% such that at least 99% of pores are interconnected and have diameters of at most 200 microns, (b) an outer protective layer and optionally (c) a filler. In another aspect, the invention includes a method of making an artificial scaffold wherein a scaffolding material is extruded into a coolant and thereby creating a porous material having a porosity of between 15-90% such that at least 99% of pores are interconnected and have diameters of at most 200 microns.

A health-care food in the form of soft-capsule, capsule, particle, tablet, or oral liquid for improving immunity and preventing and treating the injury of stomach mucosa is proportionally prepared from the oil of seabuckthorn fruit and the extract of propolis through mixing and shaping.

A freeze-dried nano-suspension of nimodipine for intravenous injection with low stimulation and high curative effect and stability contains nimodipine, surfactant and scaffolding agent. Its preparing process and application are also disclosed.

The invention relates to a gold-core-composite nano-carrier as well as a preparation method and application thereof. According to the gold-core-composite nano-carrier, a silicon dioxide modified gold nanorod (Au@SiO2) is taken as an inner core and is coated with a layer of high polymer material sensitive to temperature and pH. The gold-core-composite nano-carrier can be used for coating various drug and probe molecules and transporting the drug and probe molecules to disease sites, and therefore, the targeted therapy is realized. After absorbing near-infrared laser, the gold-core-composite nano-carrier or a drug-loading nanoparticle can emit fluorescent light, and partial optical energy can be converted into heat to be applied to biological imaging, chemotherapy and thermal therapy; the gold-core-composite nano-carrier further has the pH-sensitive property and is capable of effectively releasing the drug molecules in a weakly acidic tumor microenvironment and cell lysosome; multiple tumor therapy functions of the gold-core-composite nano-carrier can be combined in use, so that the defects of a single tumor therapy method are overcome; the gold-core-composite nano-carrier is suitable for being applied to the complex tumor diagnosis and treatment.

The present invention provides a powder superior in water-dispersibility/solubility, workability and tabletability, which contains an oil component containing a bioactive substance, a water-soluble polymer, a saccharide other than polysaccharides and a surfactant, at a particular ratio. The powder can be utilized for food, food with nutrient function claims, food for specified health uses, nutritional supplement, nutritional product, animal drug, drinks, feed, pharmaceutical product, quasi-drug, cosmetic and the like.

The invention discloses a novel diagnosis and treatment agent with integrated functions of copper ion fluorescence detection and drug therapy and a preparation method of the novel diagnosis and treatment agent. According to the novel diagnosis and treatment agent, an energy donor and an energy receptor are combined together through the interactionof covalent bonds, the energy donor is an up-conversion luminescence nanocrystalline (UCNPs) with a core-shell structure, one end of the nanocrystalline is provided with -N=C=0 groups, the energy receptor is a rhodamine b derivative for singly detecting copper ions, and the surface of the UCNPs is further loaded with mesoporous silica as a drug loading channel; and the UCNPs is subjected to mesoporous silica coating by virtue of a reverse micelle method and is hydrolyzed with3-(triethoxy silyl)propyl isocyanate with one end provided with silicon hydroxyl, the energy donor and an energy receptor dye molecule with one end provided with amino are subjected to bonded through the covalent bonds, and finally a duct of mesoporous silica is loaded with a drug molecule DOX by virtue of an electrostatic effect and a hydrogen bond. The novel diagnosis and treatment agent has high sensitivity and selectivity and low background fluorescence influence.

The invention relates to a tilmicosin soluble powder. The tilmicosin soluble powder is characterized by comprising the following ingredients in percentage by mass: 5-25% of tilmicosin, 3-15% of a cosolvent, 1-3% of a solubilizer, 3-8% of PEG and filler. The invention further provides a preparation method of the tilmicosin soluble powder. According to the tilmicosin soluble powder and the preparation method thereof disclosed by the invention, the preparation process is simple, only simple mixing is needed, the raw materials are all commercially available, low in price and easily available, and the obtained compound preparation is stable in performance; because of addition of the cosolvent and the solubilizer, the tilmicosin soluble powder is good in dissolving property, quite suitable for applications in clinic aspects, capable of meeting the relevant provisions of pharmacopoeia, suitable for industrialized large-scale production, and quite wide in application prospect. The tilmicosin soluble powder has a high practical value.

The invention discloses a self-assembly starch nanoparticle and a preparation method thereof. According to the method, octenyl succinic acid starch is dissolved in dimethyl sulfoxide solution to obtain a solution A; the degree of substitution of the octenyl succinic acid starch is 0.4-1.5; distilled water is added into the solution A to obtain an octenyl succinic acid starch/ dimethyl sulfoxide/ water mixed solution system; the volume ratio of solution A to distilled water is 0.5:1 to 2:1; the mixed solution is transferred to a dialysis bag, the dialysis bag is put in dialysate distilled water for dialysis; and impurities in the dialyzed suspension are filtered by use of a microporous filter membrane. The self-assembly starch nanoparticle is free of an emulsifier and organic solvent residue, high in ball forming rate, has a particle size effectively controlled between 50-200nm, and can be used as a carrier for drug and cosmetic active ingredients.

A bifidobacteria colostrum-soluble soft capsule and a preparation method thereof. The invention relates to a bifidobacterium colon-soluble soft capsule and a preparation method thereof. The soft capsule includes two parts, a content and a rubber skin, and the shell of the soft capsule is processed to make it colon-soluble. The content of the soft capsule is a stable suspension prepared by mixing and stirring bifidobacterium freeze-dried powder, vegetable oil, suspending agent and wetting agent. In addition, the capsule shell has colonic solubility by impregnating the soft capsule with formaldehyde. The invention encapsulates the bifidobacterium freeze-dried powder soft capsule with vegetable oil as the carrier, has the effect of dissolving the colon, has good product stability, is convenient for transportation and storage, prolongs the shelf life, and jointly acts the bifidobacteria and vegetable oil on the colon , improve the disorder of intestinal flora, achieve the effect of laxative, and solve the pain caused by constipation. The invention is applied to the field of preparation of probiotics.

Provided herein are methods of treating, preventing, managing, and/or ameliorating leukemia or myelodysplastic syndrome comprising administering 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide or a stereoisomer or mixture of stereoisomers, an isotopologue, pharmaceutically acceptable salt, tautomer, solvate, hydrate, co-crystal, clathrate, or polymorph thereof to a patient.

Disclosed are methods for treating urinary incontinence in a mammal wherein a composition comprising a biocompatible polymer, a biocompatible solvent, and a contrast agent is delivered to the periurethral tissue of the mammal.

The invention is directed to compositions and methods for the stabilization of viral and bacterial vaccines. Vaccines of the invention are contained in VLPs with stabilizing agents such as, for example, sugar alcohols (e.g., sorbitol) and degraded gelatins. Preferably the gelatin has an average molecular weight of 10,000 kilodaltons or less. These vaccines have a substantially improved thermostability as well as long term stability. The invention is also directed to the manufacture of a vaccine or the invention and methods for the administration of a vaccine of the invention to patients.

The invention discloses a preparation method of zif-8 nanosphere loaded SERS coded gold nanoparticles for intracellular photothermal therapy. The preparation method comprises the following specific steps: (1) reacting chloroauric acid with trisodium citrate to generate 13nm gold nanoparticles; (2) labeling gold nanoparticles by using a Raman reporter DTTC, and adding sulfydryl-containing polyethylene glycol to stabilize the gold nanoparticles; (3) adding polyethylene glycol with a sulfydryl group at one end and a carboxyl group at the other end into (2), modifying the surfaces of the gold nanoparticles with a large amount of carboxyl groups, adding adriamycin and an activating agent, and reacting the materials for 24 hours to obtain drug-loaded gold nanoparticles; and (4) dispersing the drug-loaded gold nanoparticles in the step (3) into zinc nitrate and ligand dimethylimidazole, and reacting the materials to obtain the zif-8 nanosphere loaded SERS coded gold nanoparticles. The SERS coded drug-loaded nanoparticles prepared by the invention can be used for inhibiting cell transfer and intracellular photothermal therapy, and the drug is loaded on the surfaces of the gold nanoparticles to realize internalization of the drug and kill cancer cells to the maximum extent.

Drug products in the form of modified release formulations comprising the drug substance (-)-(3aR,4S,7aR)-4-Hydroxy-4m-tolylethynyl-octahydro-indole-1-carboxylic acid methyl ester (AFQ056), as well as processes for making such drug products are provided. The drug products are useful in treating patients with Parkinson's disease and exhibiting L-dopa induced dyskinesia.

The invention relates to the technical field of photothermal nanomaterials, particularly tumor-targeting nanoparticles, a preparation method and application thereof, the tumor targeting nanoparticleshave a spherical shell-core structure, comprises a PFOB core and an IR780 core liposome membrane surrounding the PFOB core, wherein the IR780 core liposome membrane comprises a liposome layer and IR780 iodide particles, and the tumor-targeting nanoparticles have a particle size range of 220 to 320 nm. The potential of the tumor targeting nanoparticles is-28.32- -19.48 mV, drug loading 3.87%-4.87%and encapsulation efficiency 85.7%-87.9%. The invention provides a tumor-targeting nanoparticle, preparation method and application thereof, which can evaluate tumor by preoperative photoacoustic imaging, CT imaging and near-infrared fluorescence imaging, optimize tumor resection under the guidance of intraoperative near-infrared fluorescence, and kill residual focus by auxiliary photothermal treatment during operation.